Skip to content
Screener

Ginkgo Bioworks DNA Reportable Segment — Merger and acquisition related expense (income)

Similar metrics at other companies

Pacific Biosciences of California logo
PACBReportable Segment — Merger-related expenses
$0—
Norfolk Southern logo
NSCReportable Segment — Merger-related expenses
$51M—
Adobe logo
ADBEReportable Segment — Acquisition-related expenses
$5M—
Fulton Financial logo
FULTReportable Segment — Acquisition-related expenses
$295.5K-96.9%
Zscaler logo
ZSReportable Segment — Acquisition-related expenses
$1.78M—
Concentrix Corporation logo
CNXCReportable Segment — Acquisition-related and integration expenses
$65.51M+290%

Other financials

Income statement

See full
Revenue$20.2M-48.5%
Gross profit$18.4M-45.4%
Operating income-$58.5M-0.7%
Net income-$46.7M+22.5%
EPS (diluted)-$1.42+27.6%

Balance sheet

See full
Cash & equivalents$172.0M-31.6%
Total debt$404.1M-5.8%
Total equity$420.3M-31.4%
Total assets$990.0M-19.6%

Cash flow

See full
Operating cash flow-$44.3M-10.0%
CapEx$2.6M+6,792%
Free cash flow-$46.9M-16.4%

Valuation

See full
Market cap$515.15M-26.8%
Enterprise value$747.25M-15.2%
P/S4.6×+1.3×

Profitability

See full
Gross margin91.8%—
Operating margin-259.9%+1,304pp
Net margin-260%+718pp
FCF margin-156.3%+38.7pp

Returns & leverage

See full
Return on equity-56.3%+23.1pp
Debt / equity1×+0.3×
Current ratio4.6×-0.8×

Where this comes from

Reported directly by Ginkgo Bioworks in its filing.

Tagged under the XBRL concept us-gaap:BusinessCombinationAcquisitionRelatedCosts.

The source filing: Ginkgo Bioworks’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 4:09 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001628280-26-054298
Line itemThree Months Ended June 30, 20262025Six Months Ended June 30, 20262025
General and administrative (1)11,10815,98623,83135,639
Stock-based compensation (2)8,03718,77024,74536,483
Depreciation and amortization12,31515,24925,11430,071
Restructuring charges (3)—3,566—8,032
Carrying cost of excess space (net of sublease income) (4)14,23312,41330,07424,088
Merger and acquisition related expense (income) (5)1,106(3,617)1,106(4,535)
Other (income) expense, net (6)(1,355)(4,686)3,410(2,436)
Loss from continuing operations before income taxes$(57,193)$(53,477)$(133,332)$(136,699)

Item 1. Financial Statements (Unaudited)

FAQ

What is Ginkgo Bioworks's reportable segment — merger and acquisition related expense (income)?
Ginkgo Bioworks (DNA) reported reportable segment — merger and acquisition related expense (income) of $1.11M in Q2 2026.
What does reportable segment — merger and acquisition related expense (income) mean?
This captures the costs or gains directly associated with the integration or acquisition of businesses within a specific segment. It is used to isolate the financial impact of inorganic growth activities from the segment's core operating performance.

Ask your AI about Ginkgo Bioworks's reportable segment — merger and acquisition related expense (income).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude